Accordingly, therapeutic blockade of FASN activity may be effective in the prevention of refractoriness to endocrine therapy in HER2-negative breast carcinomas subtypes where FASN overexpression results from HER2/HER3 signaling. Here, ERBB2 is linked to breast carcinoma.